We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
-$68.5M
Cap. Flow %
-9.65%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.52M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 10.24%
2 Consumer Discretionary 1.47%
3 Technology 1.37%
4 Financials 1.09%
5 Consumer Staples 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.12M 0.44%
193
+48
+33% +$7.71K
IONS icon
27
Ionis Pharmaceuticals
IONS
$9.14B
$3.11M 0.44%
78,000
+23,312
+43% +$913K
CAN
28
PUT
Canaan Creative
CAN
$178M
$3.05M 0.43%
+3,742
New +$42.5K
KUST
29
PUT
Kustom Entertainment Inc
KUST
$639K
– –
0
– –
ASXC
30
DELISTED
Asensus Surgical, Inc.
ASXC
$2.95M 0.42%
931,414
-1,369,647
-60% -$3.42M
MARA icon
31
PUT
Marathon Digital Holdings
MARA
$4.34B
$2.86M 0.4%
+912
New +$28.9K
ATER icon
32
PUT
Aterian
ATER
$4.21M
$2.8M 0.39%
+160
New +$37.4K
AMRN
33
CALL
Amarin Corp
AMRN
$293M
$2.75M 0.39%
313
+36
+13% +$3.54K
GLBS icon
34
Globus Maritime Ltd
GLBS
$60.9M
$2.72M 0.38%
+700,427
New +$3.18M
AUTL
35
Autolus Therapeutics
AUTL
$386M
$2.66M 0.37%
400,050
-125,180
-24% -$777K
PCVX icon
36
Vaxcyte
PCVX
$7.88B
$2.66M 0.37%
117,994
-60,998
-34% -$1.25M
VXX icon
37
CALL
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$159M
$2.58M 0.36%
+55
New +$32.8K
ASLN
38
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.52M 0.36%
19,132
-1,297
-6% -$162K
RKDA icon
39
PUT
Arcadia Biosciences
RKDA
$1.37M
$2.48M 0.35%
209
+113
+118% +$12.3K
NCTY
40
PUT
The9 Ltd
NCTY
$70.6M
$2.41M 0.34%
169
+153
+956% +$27.8K
KRBP
41
DELISTED
Kiromic BioPharma, Inc. Common Stock
KRBP
$2.41M 0.34%
+16,684
New +$4.18M
RIOT icon
42
Riot Platforms
RIOT
$8.03B
$2.37M 0.33%
63,000
+45,000
+250% +$1.61M
OCUL icon
43
CALL
Ocular Therapeutix
OCUL
$1.85B
$2.37M 0.33%
1,668
+702
+73% +$10.7K
RDHL
44
Redhill Biopharma
RDHL
$4.44M
$2.34M 0.33%
340
-291
-46% -$2.01M
LFWD icon
45
ReWalk Robotics
LFWD
$19.6M
$2.31M 0.33%
16,294
+914
+6% +$143K
BETS
46
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
$2.29M 0.32%
+69
New +$2.63M
NBEV
47
CALL
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$2.25M 0.32%
+10,113
New +$23.6K
ZVRA icon
48
CALL
Zevra Therapeutics
ZVRA
$575M
$2.22M 0.31%
1,735
-2,458
-59% -$26.4K
CHRN
49
ChronoScale Holdings
CHRN
$2.94B
$2.22M 0.31%
26,858
-1,366
-5% -$115K
OCUL icon
50
PUT
Ocular Therapeutix
OCUL
$1.85B
$2.21M 0.31%
1,558
+328
+27% +$4.99K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $68.5M in Q2 2021, closing 43 positions and reducing 50 holdings. Its most notable exit was PENN Entertainment, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Sabby Management opened a new position in Aterian worth $6.33M.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.